Galanin: The Sleep-Promoting Peptide
Peptides and Sleep
85% of VLPO sleep neurons
Approximately 85% of sleep-active neurons in the ventrolateral preoptic area contain galanin, making it the dominant neuropeptide in the brain's primary sleep switch.
Kroeger et al., Nature Communications, 2018
Kroeger et al., Nature Communications, 2018
View as imageA 29-amino-acid neuropeptide discovered in 1983 from porcine intestinal extracts turns out to be one of the most important molecules in human sleep regulation. Galanin is expressed in approximately 85% of sleep-active neurons in the ventrolateral preoptic area (VLPO), the brain region that functions as the primary "sleep switch," and chemogenetic activation of these galanin-expressing neurons is sufficient to induce sleep in awake animals. Post-mortem human studies established a direct correlation between the number of galanin-immunoreactive neurons in the intermediate nucleus of the hypothalamus (the human VLPO homolog) and the amount of consolidated sleep in elderly individuals. Yet galanin's roles extend far beyond sleep. The peptide modulates feeding behavior, pain processing, cognition, mood, and neuroendocrine function through three distinct receptor subtypes with sometimes opposing effects.[1] This article covers the full evidence landscape for galanin as a neuropeptide, from molecular biology through sleep physiology to its diverse non-sleep functions. For detailed coverage of specific subtopics in peptide sleep biology, see our articles on orexin/hypocretin, the wakefulness peptide, growth hormone peptides and deep sleep, neuropeptide S and arousal, suvorexant and lemborexant, and the complete peptide sleep map.
Key Takeaways
- Galanin is present in approximately 85% of sleep-active neurons in the VLPO, the brain's primary NREM sleep-promoting center (Kroeger et al., Nature Communications, 2018)
- Chemogenetic activation of VLPO galanin neurons increases NREM sleep, reduces body temperature, and induces sleep in an animal model of insomnia
- The galanin peptide family acts through three G-protein-coupled receptors (GalR1, GalR2, GalR3) with distinct and sometimes opposing effects on neuronal excitability and behavior (Lang et al., Pharmacological Reviews, 2007)
- Galanin-like peptide (GALP) produces a dichotomous feeding response: transient appetite increase followed by appetite suppression and weight reduction (Sanadgol et al., 2025)
- GalR1 and GalR3 stimulation produces depression-like behaviors in animal models, while GalR2 stimulation reduces them (Kask et al., Life Sciences, 1997)
- Neuropeptide Y also promotes sleep and suppresses ACTH and cortisol in humans, acting through complementary pathways to galanin (Antonijevic et al., 2000)
What Is Galanin?
Galanin is a neuropeptide first isolated by Tatemoto and colleagues in 1983 from porcine intestinal extracts using a chemical detection method that identifies peptides with C-terminal amidation. The name "galanin" reflects its N-terminal glycine and C-terminal alanine residues. In most mammals, galanin is 29 amino acids long; in humans, it is 30 amino acids and uniquely lacks C-terminal amidation, a structural difference whose functional significance remains debated.
The peptide is encoded by the GAL gene on chromosome 11q13.3 in humans. Galanin is synthesized as a 123-amino-acid preprogalanin that undergoes proteolytic processing to yield the mature peptide. The first 15 N-terminal residues are highly conserved across vertebrate species and are sufficient for receptor binding and biological activity, while the C-terminal portion is more variable and modulates receptor subtype selectivity.[1]
The Galanin Peptide Family
Galanin is the founding member of a small peptide family that includes galanin-like peptide (GALP) and the splice variant alarin. GALP is a 60-amino-acid peptide that shares residues 9-21 with galanin and was identified in the porcine hypothalamus. Unlike galanin, GALP acts preferentially through GalR2 and has distinct effects on feeding and reproduction. Central administration of GALP in animal models produces a dichotomous feeding response: a short-term orexigenic (appetite-stimulating) effect followed by a longer-term anorexigenic effect and body weight reduction.[2]
Alarin is a 25-amino-acid peptide generated by alternative splicing of the GAL gene. It does not bind classical galanin receptors and appears to signal through an unidentified receptor. Alarin has been implicated in vasoconstriction, food intake, and inflammation, but its physiological roles are less well characterized than those of galanin or GALP.
Three Receptors, Three Profiles
Galanin acts through three G-protein-coupled receptors: GalR1, GalR2, and GalR3. All three belong to the rhodopsin-like GPCR superfamily, but they couple to different intracellular signaling cascades and produce different functional outcomes.
GalR1 couples to Gi/Go proteins, inhibiting adenylyl cyclase, opening inwardly rectifying potassium channels (GIRKs), and hyperpolarizing neurons. GalR1 is the dominant galanin receptor in the hypothalamus, hippocampus, and amygdala. Its activation generally produces inhibitory effects: reduced neuronal firing, suppressed neurotransmitter release, and decreased excitability. In the context of sleep, GalR1 activation on wake-promoting neurons may contribute to their silencing during NREM sleep.
GalR2 couples to Gq/11 proteins, activating phospholipase C and increasing intracellular calcium. GalR2 activation is generally excitatory and has been linked to neurotrophic, neuroprotective, and antidepressant-like effects. This makes GalR2 pharmacologically distinct from GalR1 and GalR3.
GalR3 couples to Gi/Go proteins similar to GalR1 and is expressed at lower levels, primarily in the hypothalamus and pituitary. GalR3 has been linked to anxiety and depression-like behaviors in animal models.[3]
The existence of three receptors with distinct signaling profiles explains galanin's paradoxical ability to promote sleep in one brain region while modulating feeding, pain, or cognition in another. The net effect of galanin depends on which receptor subtype dominates in a given circuit.
Distribution in the Brain and Periphery
Galanin is one of the most widely distributed neuropeptides in the mammalian nervous system. In the brain, dense galanin expression occurs in the hypothalamus (VLPO, arcuate nucleus, paraventricular nucleus), basal forebrain (medial septum, diagonal band of Broca), brainstem (locus coeruleus, dorsal raphe, nucleus of the solitary tract), and spinal cord dorsal horn. Each of these locations corresponds to a specific functional role: the VLPO for sleep, the arcuate for feeding and reproduction, the locus coeruleus for arousal and mood, and the dorsal horn for pain processing.
In the periphery, galanin is present in the gastrointestinal tract (where it modulates gut motility and secretion), pancreatic islets (where it inhibits insulin secretion), the adrenal gland, and sensory neurons of the dorsal root ganglia. The peptide's peripheral distribution explains its involvement in metabolic regulation, stress responses, and inflammatory signaling in addition to its central nervous system roles.
Galanin is co-localized with other neurotransmitters in region-specific patterns. In the VLPO, galanin is co-released with GABA. In the locus coeruleus, galanin is co-released with norepinephrine. In the dorsal raphe, galanin is co-released with serotonin. In the basal forebrain, galanin is co-released with acetylcholine. These co-expression patterns mean that galanin modulates the very transmitter systems it accompanies, typically in an inhibitory direction through GalR1.
Galanin and Sleep
The VLPO Sleep Switch
The ventrolateral preoptic area was identified as the brain's primary sleep center in 1996 by Sherin and colleagues, who showed that VLPO neurons are selectively active during sleep and contain the inhibitory neurotransmitters GABA and galanin. Approximately 80-85% of sleep-active VLPO neurons express galanin, making it the dominant neuropeptide marker for sleep-promoting circuits in the mammalian brain.
VLPO galanin/GABA neurons project to and inhibit all major arousal centers: the tuberomammillary nucleus (histamine), locus coeruleus (norepinephrine), dorsal raphe (serotonin), laterodorsal and pedunculopontine tegmental nuclei (acetylcholine), and lateral hypothalamus (orexin/hypocretin). This reciprocal inhibition between sleep-promoting VLPO neurons and wake-promoting arousal centers creates a bistable "flip-flop" switch that produces rapid transitions between sleep and wakefulness rather than intermediate states.
Chemogenetic activation experiments provided causal evidence for galanin's sleep-promoting role. When researchers used designer receptors (DREADDs) to selectively activate VLPO galanin neurons in mice, the animals showed increased NREM sleep, reduced body temperature, and shortened sleep latency. These activated galanin neurons could induce sleep even in a mouse model of insomnia. Low-frequency optogenetic stimulation (1-4 Hz) of VLPO galanin neurons also promoted sleep, though high-frequency stimulation (above 8 Hz) paradoxically caused waking, likely through depolarization block.
Homeostatic Sleep Regulation
Beyond simply promoting sleep onset, galanin is required for homeostatic sleep rebound, the compensatory increase in sleep that follows sleep deprivation. When animals are kept awake longer than normal, galanin expression increases in the VLPO proportionally to the duration of wakefulness, and the subsequent rebound sleep requires intact galanin signaling.
Single-nucleus RNA sequencing of the mouse preoptic hypothalamus identified a specific galanin neuronal subtype that is selectively activated during recovery from sleep deprivation. This subtype expresses a distinct transcriptional profile compared to other galanin neurons in the region, suggesting that the brain dedicates a specific neuronal population to tracking sleep debt and initiating recovery.
Galanin and Aging
The correlation between galanin neuron count and sleep quality in aging has clinical significance. Older adults progressively lose galanin-immunoreactive neurons in the intermediate nucleus (the human VLPO homolog), and this loss correlates directly with reduced total sleep time and sleep fragmentation. The age-related decline in galanin neurons may partially explain the sleep disruption that accompanies normal aging, independent of sleep disorders like obstructive sleep apnea.
This finding positions galanin as a potential biomarker and therapeutic target for age-related sleep decline. If galanin neuron loss drives sleep deterioration, then pharmacological GalR1 agonists or neuroprotective strategies that preserve these neurons could address a root cause of geriatric insomnia.
Galanin and Body Temperature
VLPO galanin neuron activation simultaneously promotes sleep and reduces body temperature, reflecting the natural coupling of thermoregulation and sleep. Body temperature drops during NREM sleep in healthy individuals, and this decline is partly mediated by VLPO projections to thermoregulatory centers. The dual sleep-thermoregulatory function of galanin neurons may explain why warm environments facilitate sleep onset and why fever disrupts sleep architecture.
The temperature connection also has clinical implications. The sleep-promoting effects of warm baths before bedtime, documented in multiple clinical studies, may partly operate through the VLPO's temperature-sensing galanin neurons. As peripheral body temperature rises and then falls after a warm bath, VLPO galanin neurons respond to the declining core temperature signal by increasing their firing rate and promoting sleep.
For context on how other neuropeptides influence sleep architecture, see our article on the complete peptide sleep map.
Galanin in Feeding and Appetite
Galanin was one of the first neuropeptides recognized as an orexigenic (appetite-stimulating) signal in the hypothalamus. Injection of galanin into the paraventricular nucleus increases food intake in rats, with a preferential effect on fat consumption. This feeding effect is mediated primarily through GalR1 in the hypothalamus.[3]
Galanin-like peptide (GALP) shows a more complex feeding profile. Central GALP administration produces an initial appetite increase followed by a sustained decrease in food intake and body weight reduction.[2] This biphasic response suggests that GALP engages both orexigenic and anorexigenic circuits, possibly through sequential activation of different receptor populations.
The connection between galanin's sleep and feeding roles is not coincidental. Sleep and feeding are reciprocally regulated: sleep deprivation increases appetite (partly through altered neuropeptide signaling), and large meals promote sleepiness. Sex-specific effects of sleep restriction on food intake are mediated partly through changes in neuropeptide expression in the hypothalamus, where galanin, orexin, and NPY circuits overlap.[4] Neuropeptide Y, which also promotes both sleep and feeding, acts through complementary pathways, with NPY promoting sleep and simultaneously suppressing ACTH and cortisol in human subjects.[5]
Galanin in Pain and Nociception
Galanin is upregulated in dorsal root ganglion (DRG) neurons after peripheral nerve injury, where it modulates pain signaling through opposing receptor-mediated mechanisms. GalR1 activation on spinal cord neurons is generally inhibitory and produces analgesia, while GalR2 activation can be either analgesic or pro-nociceptive depending on the spinal cord lamina and the type of pain stimulus.
In the spinal dorsal horn, galanin inhibits nociceptive transmission by hyperpolarizing second-order sensory neurons, reducing their responsiveness to incoming pain signals. This mechanism is distinct from opioid-mediated analgesia and represents an independent endogenous pain control system. Galanin knockout mice show enhanced nociceptive responses, confirming the peptide's role as an endogenous analgesic.
UVB irradiation of the skin induces rapid changes in galanin, substance P, and c-Fos expression in cutaneous nerve fibers, demonstrating that galanin participates in the acute neuroimmune response to tissue damage.[6] This suggests a broader role for galanin in peripheral tissue protection beyond classical nociception.
The sleep-pain intersection through galanin is clinically relevant. Chronic pain disrupts sleep, and sleep deprivation lowers pain thresholds, creating a bidirectional cycle. Galanin's dual involvement in both sleep promotion and pain inhibition positions it at the intersection of this cycle. A GalR1 agonist that promoted sleep and simultaneously reduced pain transmission in the spinal cord would, in theory, break the pain-insomnia cycle from both directions. This dual-target potential distinguishes galanin from most other analgesic or hypnotic mechanisms.
Galanin in Cognition and Neurodegeneration
Galanin is overexpressed in the basal forebrain of Alzheimer's disease patients, where it inhibits cholinergic neurotransmission through GalR1-mediated hyperpolarization of cholinergic neurons. Central galanin administration impairs performance on memory tasks in rodents, leading to the hypothesis that galanin overexpression in AD contributes to cognitive decline by suppressing the already compromised cholinergic system.[3]
However, galanin may also be neuroprotective. GalR2 activation promotes neuronal survival through trophic factor signaling, and galanin upregulation in AD may represent an attempted neuroprotective response rather than a primary pathological mechanism. Whether galanin's cognitive effects are net harmful or protective in neurodegeneration remains unresolved and likely depends on the ratio of GalR1 to GalR2 activation in specific circuits.
Galanin's involvement in Alzheimer's pathology is distinct from beta-amyloid and tau pathways and represents a neuropeptide-level mechanism of cognitive decline. The observation that galanin is upregulated specifically in brain regions showing cholinergic neuron loss suggests a compensatory response that overshoots, creating inhibitory excess. This interpretation is supported by the finding that GalR2-selective agonists can rescue cholinergic function in animal models while GalR1 antagonists prevent galanin-mediated cognitive impairment. For more on neuroprotective peptide signaling, see our article on BDNF, the brain peptide that builds new neural connections.
Galanin and Mood
Galanin's relationship with depression operates through its modulation of serotonin and norepinephrine, the two neurotransmitter systems targeted by most antidepressant drugs. Galanin is co-expressed with serotonin in dorsal raphe neurons and with norepinephrine in locus coeruleus neurons.
GalR1 and GalR3 stimulation produces depression-like behaviors in animal models, consistent with their inhibitory effects on monoamine release. GalR2 stimulation produces the opposite: reduced depression-like behaviors and anxiolytic effects.[3] This receptor-specific bidirectionality makes galanin a complex therapeutic target. GalR2 agonists and GalR3 antagonists have been proposed as potential antidepressant strategies, but neither has advanced beyond preclinical testing.
The sleep-mood connection through galanin is clinically relevant. Insomnia is both a symptom and a risk factor for major depression. If galanin neuron loss contributes to both sleep disruption and altered monoamine regulation in the same patients, then galanin-targeted therapies could potentially address both dimensions simultaneously.
Galanin and Seizure Protection
Galanin also functions as an endogenous anticonvulsant. The peptide inhibits seizure activity in multiple animal models of epilepsy, and galanin knockout mice show increased seizure susceptibility. GalR1 activation in the hippocampus hyperpolarizes glutamatergic neurons, reducing excitatory transmission and raising the threshold for seizure propagation.
Engineered galanin analogs and gene therapy approaches delivering galanin to the hippocampus have shown anticonvulsant efficacy in preclinical models. This application is mechanistically consistent with galanin's broader role as an inhibitory neuromodulator. The same GalR1-mediated neuronal silencing that promotes sleep in the VLPO and suppresses pain in the spinal cord also suppresses pathological hyperexcitability in the hippocampus.
The Broader Peptide Sleep Network
Galanin does not regulate sleep in isolation. It operates within a network of neuropeptides that includes orexin/hypocretin (wake-promoting), neuropeptide S (arousal), melanin-concentrating hormone (REM sleep), and neuropeptide Y (NREM sleep). The flip-flop switch between sleep and wakefulness is maintained by reciprocal inhibition between galanin/GABA neurons in the VLPO and orexin neurons in the lateral hypothalamus.
When orexin signaling is absent, as in narcolepsy type 1, the flip-flop switch becomes unstable, producing inappropriate intrusions of sleep into wakefulness and wakefulness into sleep. This clinical observation underscores how the balance between sleep-promoting (galanin) and wake-promoting (orexin) peptides determines sleep-wake stability. For deeper coverage of orexin's role, see our article on orexin/hypocretin and narcolepsy.
The therapeutic exploitation of this network has already produced approved drugs. Suvorexant and lemborexant are dual orexin receptor antagonists (DORAs) that treat insomnia by blocking the wake-promoting peptide signal rather than enhancing the sleep-promoting signal. These drugs validate the concept that peptide signaling controls the sleep-wake switch, though they target the orexin side rather than the galanin side. A galanin-based approach would theoretically activate sleep promotion directly rather than disinhibiting it by blocking wake signals. For details on how DORAs work clinically, see suvorexant and lemborexant.
Melanin-concentrating hormone (MCH), another hypothalamic neuropeptide, promotes REM sleep specifically and is produced by neurons intermingled with orexin neurons in the lateral hypothalamus. The three-way interaction between galanin (NREM), MCH (REM), and orexin (wake) neurons creates a coordinate system that determines not just whether an organism sleeps, but what type of sleep it enters. Disruption of any one vertex of this triangle alters overall sleep architecture.
Neuropeptide S occupies a different position in this network. Rather than promoting or maintaining sleep, neuropeptide S produces robust arousal and anxiolytic effects through its dedicated receptor (NPSR1). Neuropeptide S-expressing neurons are concentrated in the brainstem, anatomically positioned to drive wakefulness through ascending arousal pathways. For dedicated coverage, see neuropeptide S and arousal.
Growth hormone secretion is tightly linked to slow-wave (deep) sleep, and growth hormone-releasing peptides can modulate sleep architecture. For this connection, see growth hormone peptides and deep sleep.
Casein-derived sleep-enhancing peptides from bovine milk represent an emerging area of research connecting dietary peptides to sleep quality through mechanisms that may complement endogenous neuropeptide signaling.[7]
Evidence Gaps and Open Questions
Several critical questions remain. First, the specific galanin receptor subtype responsible for sleep promotion in the VLPO has not been definitively identified. While GalR1 is the most abundant galanin receptor in the hypothalamus, conditional knockout studies targeting GalR1 specifically in VLPO neurons have not been reported.
Second, the mechanism by which galanin promotes sleep is not fully separated from GABA's role. Since VLPO sleep neurons co-release GABA and galanin, the independent contribution of each transmitter to sleep induction, maintenance, and homeostatic rebound is difficult to parse. Galanin may amplify GABA's inhibitory effects, extend the duration of inhibition, or engage distinct postsynaptic mechanisms.
Third, whether galanin replacement or GalR1 agonist therapy could treat age-related insomnia is entirely theoretical. No galanin receptor-targeted drugs have entered clinical trials for sleep disorders. The challenge is delivering galanin receptor agonists to the VLPO without affecting galanin signaling elsewhere in the brain, where the peptide regulates feeding, pain, cognition, and mood through different receptor subtypes.
The relationship between galanin and exercise-induced changes in sleep quality is unexplored. Exercise improves sleep and increases beta-endorphin levels, but whether exercise also modulates galanin expression in sleep circuits is unknown.
The pharmacological challenge of targeting galanin receptors in a region-specific manner is not trivial. A systemic GalR1 agonist designed for sleep would also affect GalR1 in the hippocampus (impairing cognition), dorsal raphe (altering mood), and hypothalamus (changing appetite). The anatomical specificity problem that limits many neuropeptide-based therapeutic strategies applies forcefully to galanin, where the same receptor subtype mediates both desired (sleep) and undesired (cognitive impairment, mood alteration) effects depending on the brain region.
The Bottom Line
Galanin is the dominant neuropeptide in the brain's primary sleep switch, expressed in approximately 85% of VLPO sleep-active neurons. Activation of these neurons is sufficient to induce NREM sleep, and galanin neuron loss correlates with age-related sleep decline in humans. Beyond sleep, galanin modulates feeding, pain, cognition, and mood through three receptor subtypes with distinct signaling profiles. No galanin-targeted therapies have reached clinical trials for sleep disorders, but the peptide's central role in sleep homeostasis makes it a compelling target.